Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

7:21 AM ET 8-K
Financial Results Jade Biosciences, Inc. JBIO

Jade Biosciences Financial Results

Jade Biosciences reported third quarter 2026 financial results, highlighting a cash position of $476 million which is expected to fund operations into Q4 2028. The company is preparing to initiate its Phase 3 EVERGREEN trial for JADE101 in IgA nephropathy ahead of schedule in Q4 2026.

Term
Q3 2026

“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile.”

Tom Frohlich, Chief Executive Officer of Jade
7:13 AM ET 10-Q
Financial Results Immunic, Inc. IMUX

Immunic Q3 2026 Results: Net Loss of $42.3M, Loss Widens

Immunic, Inc. reported a net loss of $109.0 million for the nine months ended September 30, 2026, compared to $77.9 million in the prior year, driven by increased research and development and general and administrative expenses. The company significantly strengthened its liquidity, ending the period with $132.0 million in cash following a $187.3 million private placement in February 2026.

Key figure
Net loss $42.3M
7:11 AM ET 10-Q
Financial Results Tvardi Therapeutics, Inc. TVRD

Tvardi Therapeutics Q3 2026 Results: Net Loss of $6.12M, Loss Widens

Tvardi Therapeutics reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $10.9 million loss in the prior year period. The company strengthened its liquidity by raising $13.3 million through an at-the-market equity facility, ending the quarter with $22.3 million in cash and cash equivalents.

Key figure
Net loss $6.12M
7:06 AM ET 8-K
Financial Results Tvardi Therapeutics, Inc. TVRD

Tvardi Therapeutics Financial Results

Tvardi Therapeutics reported third quarter 2026 financial results and provided updates on its STAT3 inhibitor pipeline, including plans to advance TTI-109 into clinical development for ulcerative colitis in 2027. The company also confirmed it expects a topline readout for its Phase 1b/2 study of TTI-101 in hepatocellular carcinoma in early Q1 2027.

Term
Q3 2026

“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi
7:05 AM ET 10-Q
Financial Results Fathom Holdings Inc. FTHM

Fathom Holdings Q3 2026 Results: Net Loss of $21.8M, Loss Widens

Fathom Holdings Inc. reported a significant decline in revenue to $88.6 million for Q3 2026 compared to $115.3 million in the prior year, primarily driven by a $12.1 million impairment charge. The company's net loss widened to $21.8 million for the quarter, and total shareholders' equity decreased from $37.4 million at year-end 2025 to $1.8 million as of September 30, 2026.

Key figure
Net loss $21.8M
7:02 AM ET 10-Q
Financial Results QXO, Inc. QXO

QXO Q3 2026 Results: Net Loss of $123M, Loss Narrows

QXO, Inc. reported a significant expansion in net sales to $4.9 billion for the third quarter of 2026, driven by major acquisitions including Beacon Roofing Supply and TopBuild Corp. Despite the revenue growth, the company recorded a net loss for the nine months ended September 30, 2026, as it integrated these large-scale operations and managed increased interest expenses from acquisition-related debt.

Key figure
Net loss $123M
7:01 AM ET 10-Q
Financial Results SBC Medical Group Holdings Inc SBC

SBC Medical Group Holdings Q3 2026 Results: Net Income $15.7M, Up 22.4% YoY

SBC Medical Group Holdings reported total revenues of $150.8 million for the nine months ended September 30, 2026, a 12.5% increase year-over-year. Net income for the same period rose to $38.9 million, driven by strong performance in related party revenues and improved operational efficiency.

Key figure
Net income $15.7M · +22.4% YoY
7:01 AM ET 8-K
Financial Results Powercompute, Inc. PWCM

Powercompute Financial Results

PowerCompute reported Q3 2026 financial results, achieving net income of $0.4 million compared to a loss in the prior year, driven by fair value gains as Bitcoin prices rose 43%. The company significantly improved its balance sheet by reducing secured debt by 94% and announced the purchase of 600 new S21++ miners to increase hashrate by 10%.

Term
Q3 2026
6:56 AM ET 10-Q
Financial Results Contango Silver & Gold Inc. CTGO

Contango Silver & Gold Q3 2026 Results: Net Loss of $23M, Loss Widens

Contango Silver & Gold Inc. reported a net loss of $32.5 million for the nine months ended September 30, 2026, compared to a $12.0 million loss in the prior year, driven by increased exploration and general administrative expenses. Total assets grew significantly to $492.8 million following the Dolly Varden acquisition, which added substantial mineral property and equipment value.

Key figure
Net loss $23M
6:50 AM ET 8-K
Financial Results SBC Medical Group Holdings Inc SBC

SBC Medical Group Holdings Financial Results

SBC Medical Group reported third quarter 2026 revenue of $59 million, a 35% increase year-over-year, driven by service fee revisions and clinic network expansion. Net income attributable to the company rose 22% to $16 million, while Adjusted EBITDA grew 66% to $28 million. The company's supported clinic network expanded to 293 locations, representing a year-over-year increase of 36 locations.

Term
Q3 2026

“The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth. Revenue increased 35% year-over-year, income from operations rose 66%, and net income attributable to SBC Medical rose 22%, with a net income margin of 27% and an Adjusted EBITDA margin of 47%.”

Yoshiyuki Aikawa, Chairman and CEO

“Our MSO revenue growth is supported by two key levers: expanding our clinic network and increasing service fees per clinic. Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently.”

Yoshiyuki Aikawa, Chairman and CEO
6:50 AM ET 10-Q
Financial Results Milestone Pharmaceuticals Inc. MIST

Milestone Pharmaceuticals Q3 2026 Results: Net Loss of $25.8M, Loss Widens

Milestone Pharmaceuticals reported a significant increase in cash and cash equivalents to $144.5 million as of September 30, 2026, following the recognition of an $82.8 million royalty financing obligation. The company's accumulated deficit grew to $511.1 million, reflecting ongoing development and commercialization preparations for CARDAMYST (etripamil) nasal spray.

Key figure
Net loss $25.8M
6:26 AM ET 10-Q
Financial Results Regional Health Properties, Inc RHEP

Regional Health Properties Q3 2026 Results: Net Loss of $879K

Regional Health Properties reported a net loss of $2.9 million for the nine months ended September 30, 2026, compared to a net income of $0.7 million in the prior year period. While total revenues grew significantly to $70.6 million due to increased patient care and pharmacy revenues, the company faced higher operating expenses and an impairment loss on assets held for sale.

Key figure
Net loss $879K
6:21 AM ET 10-Q
Financial Results Blue Biofuels, Inc. BIOF

Blue Biofuels Q3 2026 Results: Net Loss of $1.39M, Loss Widens

Blue Biofuels, Inc. reported a net loss of $2,799,864 for the nine months ended September 30, 2026, compared to a loss of $1,587,132 in the prior year period. The company remains in the development stage with zero revenue, while operating expenses increased due to higher research and development costs and stock-based compensation.

Key figure
Net loss $1.39M
6:20 AM ET 10-Q
Financial Results First Choice Healthcare Solutions, Inc. FCHS

First Choice Healthcare Solutions Q3 2026 Results: Net Loss of $10.7M, Loss Widens

First Choice Healthcare Solutions reported a significant net loss of $19.1 million for the nine months ended September 30, 2026, primarily driven by $17.4 million in interest expense. The company is currently pivoting its strategy toward a network of nurse practitioner-driven primary care clinics despite having zero revenue in the current period.

Key figure
Net loss $10.7M
6:07 AM ET 10-Q
Financial Results OpenWorld, Inc. OPNW ▶ Call

OpenWorld Q3 2026 Results: Net Loss of $10.2M

OpenWorld, Inc. reported a significant net loss of $16.1 million for the nine months ended September 30, 2026, compared to a net income of $1.0 million in the prior year, primarily driven by a decrease in total revenues and a sharp increase in general and administrative expenses. The period was marked by a reverse acquisition of VerifyMe, Inc. and substantial non-cash stock-based compensation and professional fees totaling over $12 million.

Key figure
Net loss $10.2M
6:06 AM ET 10-Q
Financial Results Hyperion Defi, Inc. HYPD

Hyperion Defi Q3 2026 Results: Net Income $39.6M, Up 497.5% YoY

Hyperion DeFi, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $79.4 million compared to a net loss of $5.5 million in the prior year, primarily driven by $93.6 million in realized and unrealized gains on digital assets. Total assets grew to $146.3 million from $51.8 million at year-end 2025, reflecting substantial appreciation in the company's digital asset holdings.

Key figure
Net income $39.6M · +497.5% YoY
6:06 AM ET 10-Q
Financial Results King Resources, Inc. KRFG

King Resources Global Q2 2026 Results: Net Loss of $522K, Loss Widens

King Resources Global, Inc. is a Nevada holding company operating through subsidiaries in Hong Kong and the British Virgin Islands. The company reported 112,616,649 shares of common stock outstanding as of October 21, 2026, and is currently navigating significant regulatory risks related to PRC oversight and the Holding Foreign Companies Accountable Act.

Key figure
Net loss $522K
6:06 AM ET 8-K
Financial Results Presidio Production Co FTW

Presidio Production Financial Results

Presidio Production Company reported Q3 2026 financial results, featuring a 15% increase in net production to 26.1 MBoe/d following the acquisition of Canyon Creek. The company reported total revenue of $57.3 million and Adjusted EBITDA of $29.1 million, while declaring an increased quarterly dividend of $0.375 per share.

Term
Q3 2026

“Our third quarter results reflect continued execution of our acquisition and optimization strategy. Canyon Creek contributed its first full quarter, and our continued focus on improving the performance of our existing assets has allowed us to increase our annualized dividend to $1.50 per share. Each of these steps reinforces the acquisition model we are building to consolidate producing oil and gas assets.”

Will Ulrich, Chairman and Co-CEO

“When we closed Canyon Creek, we said the Arkoma Basin was a place to build scale through consolidation. In our first full quarter operating the assets, we moved the wells onto our production systems, right-sized compression and changed chemical vendors, and Canyon Creek helped lower our lease operating expense per Boe.”

Chris Hammack, Co-CEO and Director
6:06 AM ET 10-Q
Financial Results TCW Specialty Lending IX LLC

TCW Specialty Lending IX Q3 2026 Results: Net Income $0

TCW Specialty Lending IX LLC is a newly formed business development company that has not yet commenced investment operations as of September 30, 2026. The company reported total assets of $484,830, primarily consisting of receivables from its investment adviser for organizational and offering costs, with a net asset value of $1,000. All operating expenses incurred since inception have been reimbursed by the Investment Adviser, resulting in zero net investment income.

Key figure
Net income $0
6:05 AM ET 10-Q
Financial Results TCW Star Direct Lending LLC

TCW Star Direct Lending Q3 2026 Results: Net Income $3.2M, Down 67.0% YoY

TCW Star Direct Lending LLC reported total investments at fair value of approximately $238 million as of September 30, 2026, with a portfolio primarily consisting of senior secured debt. The company maintains a diversified industry exposure, with significant concentrations in Food Products, Hotels, Restaurants & Leisure, and Personal Care Products.

Key figure
Net income $3.2M · -67.0% YoY
6:05 AM ET 10-Q
Financial Results Tcw Specialty Lending LLC

Tcw Specialty Lending Q3 2026 Results: Net Income $5.37M

TCW Specialty Lending LLC is a newly formed business development company that commenced operations on March 2, 2026. As of September 30, 2026, the company held a diversified portfolio of debt investments across various industries, with its largest exposures in Electrical Equipment (14.9% of net assets) and Building Products (12.1% of net assets).

Key figure
Net income $5.37M
6:05 AM ET 10-Q
Financial Results TCW Steel City Senior Lending BDC

TCW Steel City Senior Lending BDC Q3 2026 Results: Net Income $7.39M, Up 427.8% YoY

TCW Steel City Senior Lending BDC reported total investments of $791.4 million as of September 30, 2026, with a portfolio primarily focused on debt investments across various industries including Building Products and Professional Services. The company maintains a significant position in short-term U.S. Treasury Bills and reported 19,659,875 common shares outstanding.

Key figure
Net income $7.39M · +427.8% YoY
6:05 AM ET 10-Q
Financial Results TCW Direct Lending VII LLC

TCW Direct Lending VII Q3 2026 Results: Net Loss of $22.5M

TCW Direct Lending VII LLC reported total investments of $1.16 billion at fair value as of September 30, 2026, with a significant concentration in debt investments across industries like Textiles, Apparel & Luxury Goods and Hotels, Restaurants & Leisure. The company's net assets stood at $400.2 million, supported by 13,734,010 common units outstanding.

Key figure
Net loss $22.5M
6:05 AM ET 10-Q
Financial Results TCW Direct Lending Viii LLC

TCW Direct Lending Viii Q3 2026 Results: Net Income $4.42M, Down 90.9% YoY

TCW Direct Lending VIII LLC reported a diverse portfolio of debt investments across industries such as automobile components, commercial services, and food products as of September 30, 2026. The company held 6,310,260 common units outstanding and maintained significant positions in term loans with varying SOFR-based interest rates and PIK components.

Key figure
Net income $4.42M · -90.9% YoY
6:05 AM ET 10-Q
Financial Results TCW Direct Lending LLC

TCW Direct Lending Q3 2026 Results: Net Loss of $5.99M, Loss Narrows

For the nine months ended September 30, 2026, TCW Direct Lending Strategic Ventures LLC reported a net decrease in members' capital from operations of $8.4 million, compared to a $4.2 million decrease in the prior year period. The decline was primarily driven by $9.7 million in net unrealized depreciation on affiliated investments, specifically related to SSI Parent, LLC common and preferred stock.

Key figure
Net loss $5.99M
6:05 AM ET 10-Q
Financial Results Reviva Pharmaceuticals Holdings, Inc. RVPH

Reviva Pharmaceuticals Holdings Q3 2026 Results: Net Loss of $2.3M, Loss Narrows

Reviva Pharmaceuticals reported a net loss of $7.9 million for the nine months ended September 30, 2026, a significant reduction from the $16.5 million loss in the prior year period. The company strengthened its liquidity through public and ATM offerings, ending the quarter with $17.5 million in cash and cash equivalents.

Key figure
Net loss $2.3M
6:05 AM ET 10-Q
Financial Results Bio Essence Corp BIOE

Bio Essence Q3 2026 Results: Net Loss of $150K

Bio Essence Corp. reported a net income of $324,992 for the nine months ended September 30, 2026, a significant improvement from a net loss of $132,890 in the prior year period. Despite this profitability, the company maintains a working capital deficit of $1,374,178 and an accumulated deficit of over $9.2 million, leading management to express substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $150K
6:05 AM ET 8-K
Financial Results Reviva Pharmaceuticals Holdings, Inc. RVPH

Reviva Pharmaceuticals Holdings Financial Results

Reviva Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2026, an improvement from a $4.0 million loss in the prior year period. The company is awaiting FDA feedback in Q4 2026 regarding a new formulation of brilaroxazine for its Phase 3 RECOVER-2 trial in schizophrenia. Reviva also noted it has filed a new composition of matter patent application that could extend protection for brilaroxazine through 2046.

Term
Q3 2026

“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully.”

Laxminarayan Bhat, Founder, President, and CEO of Reviva

“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”

Laxminarayan Bhat, Founder, President, and CEO of Reviva
6:04 AM ET 10-Q
Financial Results Aardvark Therapeutics, Inc. AARD

Aardvark Therapeutics Q3 2026 Results: Net Loss of $19.2M, Loss Widens

Aardvark Therapeutics reported a net loss of $19.2 million for the third quarter of 2026, driven by increased research and development costs. The company's cash position remains at $60.3 million as it continues to transition from its 2025 initial public offering to fund its clinical-stage metabolic disease pipeline.

Key figure
Net loss $19.2M
6:04 AM ET 6-K
Financial Results Almonty Industries Inc. ALM

Almonty Industries Q3 2026 Results: Net Income $50.2M, Up 51.4% YoY

Almonty Industries reported a 382% year-over-year revenue increase to $41.9 million for Q3 2026, driven by a surge in tungsten prices and the commencement of commercial operations at the Sangdong Mine. Net income reached $50.2 million, supported by significant non-cash gains on derivative revaluations, while the company ended the quarter with a strong cash position of $1.15 billion.

Key figure
Net income $50.2M · +51.4% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.